Treatment of venous thromboembolism and long-term prevention of recurrence: Present treatment options and ximelagatran

被引:2
|
作者
Eriksson, H [1 ]
机构
[1] Sahlgrens Univ Hosp, Dept Med, Gothenburg, Sweden
关键词
D O I
10.2165/00003495-200464001-00006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Despite the effectiveness of anticoagulant therapy for the treatment of acute venous thromboembolism and the prevention of recurrent venous thromboembolism, existing antithrombotic therapies are suboptimal. Unfractionated heparin, low-molecular-weight heparin (LMWH) and warfarin have practical limitations and carry the risk of treatment-related adverse events that restrict their clinical benefits and reduce cost-effectiveness. Efforts to achieve optimal venous thromboembolism prophylaxis by modifying the intensity of oral warfarin treatment have produced equivocal results, and there is a need for new, efficacious antithrombotic drugs providing predictable, well-tolerated oral dosing without the need for coagulation monitoring. Such agents would ideally have no significant food or drug interactions, and be suitable for both short- and long-term treatment. Ximelagatran, the first oral direct thrombin inhibitor, has the potential to fulfill many of the unmet needs in the management of venous thromboembolism.
引用
收藏
页码:37 / 46
页数:10
相关论文
共 50 条
  • [1] Treatment of Venous Thromboembolism and Long-Term Prevention of Recurrence: Present Treatment Options and Ximelagatran
    Henry Eriksson
    [J]. Drugs, 2004, 64 : 37 - 46
  • [2] Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran
    Eriksson, H
    Lundström, T
    Wåhlander, K
    Clason, SB
    Schulman, S
    [J]. THROMBOSIS AND HAEMOSTASIS, 2005, 94 (03) : 522 - 527
  • [3] Long-term treatment of venous thromboembolism
    Kearon, Clive
    Kahn, Susan R.
    [J]. BLOOD, 2020, 135 (05) : 317 - 325
  • [4] Long-term treatment for venous thromboembolism
    Couturaud, F
    Kearon, C
    [J]. CURRENT OPINION IN HEMATOLOGY, 2000, 7 (05) : 302 - 308
  • [5] Long-term Treatment of Venous Thromboembolism
    Becattini, Cecilia
    Manina, Giorgia
    [J]. CURRENT VASCULAR PHARMACOLOGY, 2014, 12 (03) : 384 - 392
  • [6] Treatment and Long-Term Management of Venous Thromboembolism
    Al-Badri, Ahmed
    Spyropoulos, Alex C.
    [J]. CLINICS IN LABORATORY MEDICINE, 2014, 34 (03) : 519 - 536
  • [7] The role of ximelagatran in the treatment of venous thromboembolism
    Schulman, S
    [J]. PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS, 2005, 34 : 18 - 24
  • [8] Economic Analysis of Rivaroxaban for the Treatment and Long-Term Prevention of Venous Thromboembolism in Portugal
    Santos, Isabel Fonseca
    Pereira, Sonia
    Mcleod, Euan
    Guillermin, Anne-Laure
    Chatzitheofilou, Ismini
    [J]. ACTA MEDICA PORTUGUESA, 2014, 27 (05): : 615 - 624
  • [9] Fondaparinux in the initial and long-term treatment of venous thromboembolism
    Pesavento, Raffaele
    Amitrano, Maria
    Trujillo-Santos, Javier
    Di Micco, Pierpaolo
    Mangiacapra, Sara
    Lopez-Jimenez, Luciano
    Falga, Conxita
    Garcia-Bragado, Fernando
    Piovella, Chiara
    Prandoni, Paolo
    Monreal, Manuel
    [J]. THROMBOSIS RESEARCH, 2015, 135 (02) : 311 - 317
  • [10] Ximelagatran for secondary prevention of venous thromboembolism
    Böger, C
    Schroll, S
    Holmer, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (06): : 618 - 618